Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Journal of Managed Care & Specialty Pharmacy|July 27, 2019
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast CancerJoseph Biskupiak, Gary Oderda, Diana Brixner, et al.The Journal of Clinical Psychiatry|October 26, 2018
Benzodiazepines, Health Care Utilization, and Suicidal Behavior in Veterans With Posttraumatic Stress DisorderRishi Deka, Craig J Bryan, Joanne LaFleur, et al.American Health & Drug Benefits|July 4, 2014
Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging MarketsAnke-Peggy Holtorf, Diana Brixner, Brandon Bellows, et al.American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 10, 2025
The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO studyDaniel C Malone, Roger Seheult, Diana Brixner, et al.Clinical Therapeutics|March 24, 2007
Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003Elaine H Morrato, Sheri Dodd, Gary Oderda, et al.Journal of Managed Care & Specialty Pharmacy|January 31, 2019
Preapproval Information Exchange: Perspectives of U.S. Population Health Decision Makers on Preferences for Early Engagement with Investigational TherapiesDiana Brixner, Tatia C Woodward, Nik Seifter, et al.Journal of Managed Care & Specialty Pharmacy|August 1, 2024
Evolving oncology care management trends in the United States: A survey among health care decision makersGary Oderda, Diana Brixner, Joseph Biskupiak, et al.Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Payer perceptions of the use of real-world evidence in oncology-based decision makingDiana Brixner, Joseph Biskupiak, Gary Oderda, et al.Current Medical Research and Opinion|September 13, 2007
How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programsRobert J Valuck, Elaine H Morrato, Sheri Dodd, et al.American Health & Drug Benefits|April 12, 2019
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for BrodalumabDiana Brixner, Gary Oderda, Joseph Biskupiak, et al.Pageof 3